肿瘤药学2019，Vol.9Issue(3)：528-529,2.DOI:10.3969/j.issn.2095-1264.2019.03.37
安罗替尼联合吉非替尼治疗EGFR突变NSCLC导致严重皮下出血1例
Combination of Anlotinib and Gefitinib in the Treatment of EGFR Mutation NSCLC Causing Severe Subcutaneous Hemorrhage: A Case Report
林宝琪 1彭秀凡 1陈鹏飞 1赵昌林2
作者信息
- 1. 广州中医药大学祈福医院肿瘤二区,广东 广州,510000
- 2. 广州中医药大学祈福医院肿瘤一区,广东 广州,510000
- 折叠
摘要
Abstract
Anlotinib is a novel small-molecule multi-target tyrosine kinase inhibitor which is independently developed in China. It can effectively inhibit multiple targets. And it is attracting attention for its significant prolongation of OS and PFS. Its adverse reactions mainly include high blood pressure and proteinuria, and there are occasional reports of lethal hemoptysis. In this article, we reported a case of severe subcutaneous hemorrhage caused by anlotinib plus gefitinib treatment for advanced NSCLC patient with EGFR mutations, so as to provide a reference for clinical prevention of adverse effects of anlotinib.关键词
安罗替尼/吉非替尼/不良反应/皮下出血Key words
Anlotinib/Gefitinib/Adverse reaction/Severe subcutaneous hemorrhage分类
医药卫生引用本文复制引用
林宝琪,彭秀凡,陈鹏飞,赵昌林..安罗替尼联合吉非替尼治疗EGFR突变NSCLC导致严重皮下出血1例[J].肿瘤药学,2019,9(3):528-529,2.
